Summary

The angiotensin-receptor blocker telmisartan is equally effective in reducing cardiovascular risk as the angiotensin-converting enzyme inhibitor ramipril in patients with vascular disease or high-risk diabetes. However, the combination is no more effective than either drug alone and causes more side effects according to results from the ONTARGET Trial.